Shabinah S. Ali

A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology.

F. Edwards, J. Hardy, Sebastian Guelfi, 2015, Cell reports.

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.

C. Giaquinto, T. Puthanakit, Shabinah S. Ali, 2021, The New England journal of medicine.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression

F. Edwards, K. Blennow, J. Hardy, 2015, Brain : a journal of neurology.

Resource A Genome-wide Gene-Exp ression Analysis and Database in Transgenic Mice during Development of Amyloid or Tau Pathology Graphical

F. Edwards, J. Hardy, J. Richardson, 2015 .